Search This Blog

Tuesday, February 18, 2020

FDA OKs new dosage form of Horizon’s Procysbi

The FDA approves Horizon Therapeutics’ (HZNP -0.7%) Procysbi (cysteamine bitartrate) in tear-open packets for nephropathic cystinosis patients as young as one year old.
The cystine-depleting agent is also available in 25 mg and 75 mg capsules.

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)